Idiopathic Pulmonary Fibrosis

September 14, 2017September 14, 2017

Synairgen and Pharmaxis’ Fibrosis Therapy Candidate Is Heading for Phase 1 Clinical Trial

A potential pulmonary fibrosis therapy that Synairgen and Pharmaxis have been working on is heading for a Phase 1 clinical trial. The two created PXS-5382A as a treatment for idiopathic pulmonary fibrosis (IPF) and other ... Read more

September 13, 2017September 13, 2017

INJOURNEY Trial Data Shows Ofev-Esbriet Combo Is Safe and IPF Patients Tolerate It Well

Idiopathic Pulmonary Fibrosis, News

A combination of Boehringer Ingelheim‘s Ofev (nintedanib) and Genentech’s Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis (IPF) was safe and well tolerated, according to the latest data from the Phase 4 INJOURNEY trial. ... Read more

September 12, 2017September 12, 2017

Inventiva Announces Further Collaboration with Boehringer Ingelheim to Develop IPF Therapies

Idiopathic Pulmonary Fibrosis, News

Inventiva Pharma recently announced that Boehringer Ingelheim will extend a collaboration with the company to further advance potential treatments for fibrotic conditions including idiopathic pulmonary fibrosis (IPF). The collaboration began in May 2016 as a research and ... Read more

September 8, 2017September 8, 2017

miRagen Therapeutics to Present New Promising Data on MRG-201 at ERS 2017

Idiopathic Pulmonary Fibrosis, News

miRagen Therapeutics, a biopharmaceutical company involved in the discovery of RNA-based therapies, will present new preclinical safety and feasibility data for the therapy MRG-201 in the treatment of pulmonary fibrosis at the ... Read more

September 7, 2017September 7, 2017

Working Lung Model with Intact Vasculature Likely to Aid Research, Lung Transplants

Idiopathic Pulmonary Fibrosis, News

Researchers at Columbia University have found a way to bioengineer a “working” lung — a very complex structure — with a viable and intact blood vessel network that can support studies of ... Read more

September 6, 2017September 6, 2017

Smoking Could Influence IPF Progression, But More Research Is Needed

Idiopathic Pulmonary Fibrosis, News

A new study reported that smoking might influence the course of progression in IPF patients, although further investigation is needed to better understand this association. Previous research has shown that cigarette smoking ... Read more

August 31, 2017August 31, 2017

Protein Linked to Fibrosis Progression Will Be Focus of Start-up’s Drive for Anti-fibrotic Therapy

Idiopathic Pulmonary Fibrosis, News

Researchers in Singapore have found that inhibiting a protein called interleukin-11, or IL-11, can block fibrosis progression in mice. Enleofen Bio, a recently founded biotechnology start-up company, will try to move this finding ... Read more

August 29, 2017August 29, 2017

Three Share British Lung Foundation Grant for Lung Disease Research

Bronchiectasis, COPD, Idiopathic Pulmonary Fibrosis, News

Toby Maher, MD, a professor at Imperial College London and based at the National Heart and Lung Institute, is one of three researchers who were awarded the prestigious Chair in Respiratory Research grant ... Read more

August 28, 2017August 28, 2017

PharmAkea Completes Phase 1 Clinical Trial of Pulmonary Fibrosis Therapy PAT-1251

Idiopathic Pulmonary Fibrosis, News

PharmaAkea has completed a Phase 1 clinical trial indicating that its PAT-1251 therapy binds with an enzyme associated with pulmonary fibrosis. That suggests that it could be an effective treatment for ... Read more

August 24, 2017August 25, 2017

Ethris, AstraZeneca and MedImmune to Collaborate on Developing Respiratory Disease Therapies

Asthma, COPD, Idiopathic Pulmonary Fibrosis, News

Ethris has entered into a five-year research partnership with AstraZeneca and its subsidiary MedImmune to develop mRNA-based therapies for lung diseases. The partnership will use Ethris’ proprietary SNIM®RNA technology. The nucleic acid ... Read more